In summary, successful translation of STAT3-targeted therapies into clinical use for cancer cachexia will require a multifaceted approach: (1) comprehensive characterization of tissue-specific STAT3 mechanisms, (2) development of highly selective and bioavailable inhibitors, (3) rational combination with other therapeutic agents, (4) discovery and application of predictive biomarkers, and (5) implementation of individualized treatment plans. The gene discussed is STAT3; the disease is cancer.